Valuation: Talphera, Inc.

Market Cap 61.77M 52.91M 49.51M 45.32M 85.05M 5.91B 86.17M 585M 228M 2.97B 232M 227M 9.82B P/E 2026 *
-5.41x
P/E 2027 * -5.17x
Enterprise Value 61.77M 52.91M 49.51M 45.32M 85.05M 5.91B 86.17M 585M 228M 2.97B 232M 227M 9.82B EV / Sales 2026 *
-
EV / Sales 2027 * 309x
Free-Float
78.59%
Yield 2026 *
-
Yield 2027 * -
1 week-3.25%
Current month-7.03%
1 month-7.75%
3 months+45.99%
6 months+53.23%
Current year+4.39%
1 week 1.17
Extreme 1.17
1.27
1 month 1.11
Extreme 1.11
1.5
Current year 0.69
Extreme 0.6866
1.5
1 year 0.5
Extreme 0.5
1.57
3 years 0.38
Extreme 0.38
1.61
5 years 0.38
Extreme 0.38
23.8
10 years 0.38
Extreme 0.38
115
Manager TitleAgeSince
Chief Executive Officer 58 06/03/2017
Director of Finance/CFO 56 01/08/2017
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 60 01/08/2006
Director/Board Member 72 01/02/2010
Chairman 75 11/02/2013
Date Insider Type Main position Quantity % Market Cap.
4/2/26 A Tax

Chief Technology Officer

2,118 0.0042%
2/12/26 A Buy

Chief Technology Officer

240,000 0.5149%
2/10/26 A Tax

Chief Technology Officer

238,127 0.5109%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.25%+141.53%+9.17% 61.77M
+2.39%+12.30%+74.60%+42.26% 376B
-0.07%+1.21%+23.00%-12.63% 70.02B
+1.93%+9.64%+50.61%+153.33% 12.28B
-1.85%-0.12%-2.37%-1.49% 8.49B
-3.24%-4.12%-15.37%-2.90% 4.73B
-1.32%-1.67%-28.43%+17.57% 4.43B
-8.11%-25.49%-21.31%+13.56% 3.2B
-3.37%-5.01%+2.16%+43.64% 2.67B
-2.76%-3.99%-13.95%-6.87% 2.11B
Average -1.64%-1.95%+21.05%+25.56% 48.43B
Weighted average by Cap. +1.74%+9.70%+61.96%+35.31%

Financials

2026 *2027 *
Net sales - 200K 171K 160K 147K 275K 19.14M 279K 1.89M 739K 9.61M 751K 735K 31.8M
Net income -15.6M -13.36M -12.5M -11.44M -21.47M -1.49B -21.76M -148M -57.59M -750M -58.56M -57.28M -2.48B -18.27M -15.65M -14.64M -13.4M -25.15M -1.75B -25.49M -173M -67.46M -878M -68.6M -67.1M -2.9B
Net Debt - -
Logo Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Employees
12
Date Price Change Volume
21/08/26 $1.190 0.00% 109,538
20/08/26 $1.190 0.00% 217,476
19/08/26 $1.190 -1.65% 558,756
18/08/26 $1.210 +0.83% 425,249
17/08/26 $1.200 -2.44% 346,976
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.190USD
Average target price
3.167USD
Spread / Average Target
+166.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TLPH Stock